Alzheimer’s disease (AD) is marked by a gradual decline in cognitive function and memory impairment. This decline significantly impacts the daily lives of patients. One widely accepted cause of AD is the cholinergic hypothesis, which suggests that the selective loss of cholinergic neurons in the basal forebrain leads to decreased choline levels. Moreover, cholinergic neurotransmitters are essential for regulating higher brain functions, including memory, learning, and cognition.
To address cholinergic dysfunction in AD, researchers have widely employed cholinesterase inhibitors as therapeutic interventions. Among these, Rivastigmine (ENA 713 free base) stands out as an orally active cholinesterase inhibitor that can penetrate the blood-brain barrier (BBB). Notably, it inhibits both butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) with IC50 values of 0.037 μM and 4.15 μM, respectively.
As a classic cholinesterase inhibitor, Rivastigmine has been recommended as a first-line treatment for mild to moderate AD for decades. Furthermore, it is available in various forms, including oral capsules, transdermal patches, and nasal sprays. Thus, Rivastigmine provides multiple options for managing the symptoms of Alzheimer’s disease effectively..
Rivastigmine is a cholinesterase inhibitor for research of mild to moderate Alzheimer’s disease.
In vitro, Rivastigmine (24 μM for 24 hours) enhances neuronal morphology. It also increases the levels of proteins such as NSE, SNAP-25, and synaptophysin. Consequently, Rivastigmine has the potential to preserve both neuronal viability and structure.
In vivo, Rivastigmine (0.5-2.5 mg/kg; i.p.; administered 60 minutes before tests) significantly and dose-dependently improves behavioral impairments caused by Aluminum (100 mg/kg/day; i.p.). It enhances activity, learning, and memory in a dose-dependent manner. Notably, Rivastigmine (2.4 mg/kg, once a day, via intranasal administration) rapidly diffuses into the brain but is eliminated slowly, thus improving memory deficits associated with Alzheimer’s disease. Additionally, Rivastigmine inhibits collagen deposition and reduces the expression level of Aβ in models of Alzheimer’s induced by intra-hippocampal injection of Aβ1-42.
In summary, Rivastigmine is an orally active cholinesterase inhibitor, and improves memory deficits associated with Alzheimer’s disease.
References:
[1] Raafat A Abdel-Aal, et al. Eur J Pharmacol. 2011 Jun 1;659(2-3):169-76.
[2] Guo H, et al. Int J Pharm. 2024 Mar 5;652:123809.
[3] Bailey JA, et al. J Neurochem. 2010 Feb;112(4):843-53.